| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $78.6M | +211.9% |
| SG&A Expense | $105.9M | +685.3% |
| Operating Income | -$187.7M | -353.5% |
| Pre-tax Income | -$175.8M | -351.0% |
| Net Income | -$175.8M | -351.0% |
| EPS (Basic) | -$4.38 | -85.6% |
| EPS (Diluted) | -$4.38 | -85.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $87.9M | -48.2% |
| Short-term Investments | $203.5M | — |
| Current Assets | $293.9M | +71.5% |
| Total Assets | $331.0M | +83.2% |
| Current Liabilities | $18.7M | +62.9% |
| Long-term Debt | $49.8M | — |
| Total Liabilities | $85.9M | +270.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$69.1M | -177.0% |
| Capital Expenditures | $218K | — |
| Investing Cash Flow | -$225.7M | — |
| Financing Cash Flow | $213.0M | +18.3% |
| Free Cash Flow | -$69.3M | -177.9% |
| Stockholders' Equity |
| $245.1M |
| +55.6% |